Michael Okunewitch
Stock Analyst at Maxim Group
(0.15)
# 4,076
Out of 4,814 analysts
22
Total ratings
9.52%
Success rate
-26.91%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.17 | +498.29% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $3.08 | +354.55% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.41 | +639.64% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $0.67 | +347.76% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.68 | +488.24% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $1.38 | +769.57% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.50 | +300.00% | 2 | Aug 27, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.39 | +763.31% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $1.91 | +1,156.54% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $0.95 | +531.58% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.87 | +527.18% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $0.68 | +33,090.74% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.65 | +41.64% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.73 | +246.82% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $160 | $7.77 | +1,959.20% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.43 | +1,654.39% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.86 | +11,527.91% | 1 | Nov 30, 2021 |
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.17
Upside: +498.29%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $3.08
Upside: +354.55%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.41
Upside: +639.64%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $0.67
Upside: +347.76%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.68
Upside: +488.24%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $1.38
Upside: +769.57%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.50
Upside: +300.00%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.39
Upside: +763.31%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.91
Upside: +1,156.54%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $0.95
Upside: +531.58%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.87
Upside: +527.18%
Apr 12, 2023
Initiates: Buy
Price Target: $225
Current: $0.68
Upside: +33,090.74%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.65
Upside: +41.64%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.73
Upside: +246.82%
Mar 24, 2022
Initiates: Buy
Price Target: $160
Current: $7.77
Upside: +1,959.20%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.43
Upside: +1,654.39%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.86
Upside: +11,527.91%